Overview of study design
The A-to-Z Trial is an ongoing, 2-phase, international, multicenter, randomized study ( Figure 1 ) that focuses on 2 management questions for patients with ACS. The aggrastat phase (A phase) considers the relative value of using enoxaparin versus unfractionated heparin in combination with tirofiban and aspirin as initial therapy for high-risk patients with nSTE-ACS. Qualifying patients (below and Table I ) receive tirofiban and aspirin with subsequent randomization to open-label enoxaparin or
Figure 1
Schematic representation of the study design of the A-to-Z Trial. Patients with nSTE ACS are evaluated for A-phase inclusion and exclusion criteria (T-I). Patients who enter A phase receive tirofiban and are randomized to either enoxaparin or unfractionated heparin for 48 to 120 hours or until stabilized (T-II). Patients are re-evaluated for the risk markers for entry into the Z phase (T-III). In the Z phase patients are randomized to either aggressive simvastatin treatment or "accepted care." Patients are followed up until a primary event has occurred in 970 patients. T-I, T-II, and T-III represent key decision points for eligibility where T-I = Table I (A-phase exclusion criteria); T-II = Table II (stability criteria), and T-III = Table III (Z-phase risk criteria).
Noncardiac chest discomfort Persistent pulmonary edema or congestive heart failure requiring intubation Cardiogenic shock Uncontrolled, severe cardiac arrhythmias Known left main coronary artery stenosis unprotected by bypass grafts and amenable to bypass surgery Hemodynamically significant valvular heart disease, hypertrophic cardiomyopathy, restrictive cardiomyopathy, or congenital heart disease ST-segment elevation or new left bundle branch block where thrombolytic therapy or primary angioplasty is indicated Abnormal laboratory findings Serum creatinine >2.0 mg/dL (>177 µmol/L) Hemoglobin 1 g/dL (<100 g/L) or hematocrit <30% Platelet count <120,000/mm 3 (120 × 10 9 /L) Prothrombin time >1.3 × control or an International Normalized Ratio >1.5 Alanine aminotransferase >2 × upper limits of normal Use of the following medications Thrombolytic therapy within 24 hours of enrollment Abciximab (RepoPro) within 14 days or treatment with eptifibatide (Integrilin) within 12 hours Therapy with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, bile acid sequestrants, or nicotinic acid (>200 mg/d) within 6 weeks; fibrinates taken within 8 weeks; or probucol taken within 1 year of enrollment Cyclosporine, chronic systemic glucocorticoids, erythromycin, clarithromycin, nefazodone, mibefradil, itraconazole, ketoconazole, verapamil, or human immunodeficiency virus protease inhibitors A contraindication to anticoagulation or increased bleeding risk Any medical condition that makes survival for the duration of the study unlikely Known or suspected pregnancy History of or planned spinal/epidural anesthesia within 14 days Hypersensitivity to statins, GP IIb/IIIa receptor antagonists, heparin (including unfractionated heparin and LMWH), pork products, or aspirin History of non-exercise-related elevation of serum creatine kinase or nontraumatic rhabdomyolysis Pretreatment use, related to the index event, of tirofiban >24 hours, unfractionated heparin >24 hours, or LMWH >2 doses Table I . A-phase exclusion criteria unfractionated heparin. Additional patient evaluation and management is at the discretion of the investigator. A-phase patients are followed up for 30 days.
The subsequent Zocor phase (Z phase) of the trial tests the superiority of a strategy of early aggressive simvastatin therapy on cardiovascular outcomes over that of an "accepted care" strategy. This phase includes nSTE-ACS patients from the A phase and a separate cohort of patients with ST-elevation ACS (STE-ACS). It begins when patients finish their initial medical evaluation and are stable (Table II) . To be eligible, patients must have one of the risk features listed in Table III . Once eligible, patients are placed on an American Heart Association (AHA) step 1 diet and randomized to either an aggressive simvastatin regimen (simvastatin 40 mg daily for 30 days, followed by simvastatin 80 mg daily, irrespective of the initial low-density lipoprotein cholesterol [LDL-C] level) or an "accepted care regimen" (placebo for 4 months followed by simvastatin 20 mg daily). The trial will conclude when 970 primary events have been recorded in the Z phase.
A-phase inclusion and exclusion criteria
Entry into the A phase requires recent (within 24 hours) symptoms of ischemia at rest that last a minimum of 10 minutes, associated with electrocardiographic changes (≥0.5 mm of ST depression or transient ST elevation ≥1 mm) or elevated cardiac markers (troponin elevated to more than or equal to the upper limits of normal (ULN), elevated creatine kinase-MB ≥ULN, or if a cardiac-specific marker is not available, total creatine phosphokinase ≥2 × ULN). A threshold of 0.5 mm of ST depression was chosen as a cutoff for injury on the basis of prior studies demonstrating the prognostic utility at this level. 13, 14 Patients must be 21 to 80 years old and, if female, highly unlikely to conceive. Table I lists A-phase exclusion criteria.
A-phase design
All enrolled patients receive aspirin and tirofiban (10 µg/kg for 3 minutes followed by a maintenance infusion of 0.1 µg/kg/min for 48 to 108 h). Patients are randomized to either open-label enoxaparin (1 mg/kg every 12 h) or weight-adjusted unfractionated heparin (for patients weighing ≥70 kg, 4000 U given as an intravenous bolus followed by 900 U/h intravenously; for patients weighing <70 kg, 60 U/kg [maximum 4000 U] bolus followed by 12 U/kg/h infusion and subsequent titration to an activated partial thromboplastin time of 50 to 70 s).
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Clinical stability is defined as freedom from the following events for 12 consecutive hours Chest discomfort at rest Systolic blood pressure <90 mm Hg for >1 h or requiring hemodynamic support Pulmonary edema, acute mitral regurgitation, or acute ventricular septal defect Recurrent symptoms of ischemia with new ST-segment or T-wave changes or reinfarction Ventricular fibrillation, sustained ventricular tachycardia, complete heart block, or new-onset atrial fibrillation with uncontrolled ventricular rate (>100 beats/min) Stroke, pulmonary embolus, sepsis, and acute pericarditis Table II Table III . Z-phase inclusion high-risk criteria
The overall management strategy (early invasive versus early conservative) is at the discretion of the local investigator. The suggested duration of tirofiban infusion is 48 hours. In centers that use an early invasive strategy, tirofiban can be discontinued 12 hours after percutaneous coronary intervention (PCI). For patients randomized to LMWH, the investigator may elect to continue LMWH during catheterization or PCI or switch to unfractionated heparin for the procedure.
All A-phase patients are followed up for 30 days. It is anticipated that 50% to 60% of A-phase patients will be eligible for the Z phase. They can be randomized once stable (Table II) and tirofiban has been discontinued. The A phase and Z phase overlap during this 30-day period.
A-phase end points
The primary end point is a composite of all-cause mortality, new myocardial infarction, and documented refractory ischemia that occurs within 7 days of tirofiban initiation. Documented refractory ischemia requires either electrocardiographic changes or elevation in cardiac markers. Five secondary end points are evaluated at 7 days individually and as a composite: death, myocardial infarction, documented refractory ischemia, urgent coronary revascularization, and documented multiple clinical myocardial ischemic events. Tertiary end points are the total of primary and secondary end points and readmission for ACS at 48 hours and at 30 days.
Z-phase inclusion and exclusion criteria
All patients (nSTE-ACS or STE-ACS) who enter the Z phase must have a total cholesterol level ≤250 mg/dL. This cholesterol is locally drawn as close to presentation as possible, but it may be drawn any time before Zphase randomization. The baseline cholesterol for the Z phase is drawn at the time of Z-phase randomization and sent to a central laboratory. All patients must meet stability criteria within 120 hours (Table II) and have one of the high-risk clinical or angiographic criteria (Table III) . Patients must be between 21 and 80 years old and highly unlikely to conceive if female.
Patients are deemed ineligible if they do not meet stability criteria or high-risk clinical-angiographic criteria (Tables II and III) . They cannot be scheduled for a PCI in the 2 weeks after Z-phase randomization or scheduled for any surgical revascularization. Excluding early revascularization eliminates procedure related events (eg, elevation in cardiac biomarkers) unlikely to be modified by Z-phase therapy.
ST-elevation ACS. ST-elevation myocardial infarction is defined as chest pain associated with ST elevation of 1 mm or more in 2 contiguous leads or new left bundle branch block. "Optimal" therapy includes treatment with a thrombolytic agent or primary PCI within 12 hours of symptom onset or no reperfusion therapy if presentation is more than 12 hours after symptom onset.
Z-phase design
Z-phase patients are placed on the AHA step I diet and randomized in a double-blind fashion to either "accepted care" (placebo for 4 months followed by simvastatin 20 mg/d thereafter) or aggressive treatment (simvastatin 40 mg/d for 30 days followed by simvastatin 80 mg/d). Treatment will continue until a primary end point event has occurred in 970 patients.
Z-phase evaluation and follow-up. Clinical and laboratory assessments (blood lipid samples, serum chemistries, and urine pregnancy tests) are made at months 1, 4, and 8 and every 4 months thereafter until trial completion. If LDL-C is above 130 mg/dL at month 8 or at any subsequent visit, the site receives a lipid alert. This triggers additional dietary, lifestyle, and compliance counseling. If after 6 weeks the LDL-C remains above 130 mg/dL, the investigator may either add a bile acid sequestrant and continue the patient in the study or discontinue study drug therapy and initiate open-label therapy of choice. Patients who discontinue study drug therapy are followed up for end point analysis.
Z-phase end points
The primary end point is a composite of cardiovascular death, myocardial infarction, readmission for ACS (requiring electrocardiographic changes or elevated cardiac markers or urgent coronary revascularization) and ischemic stroke. Five secondary end points are evaluated individually and as a composite: cardiovascular death, myocardial infarction, readmission for ACS, coronary revascularization resulting from documented ischemia, and nonhemorrhagic stroke. Tertiary end points are total mortality, myocardial infarction, congestive heart failure, cardiovascular rehospitalization, total mortality/cardiovascular hospitalization, and cardiovascular mortality/cardiovascular hospitalization.
Substudies. Plasma is collected at baseline and at 4 and 8 months in all patients and is then frozen and stored for future substudies. One substudy is designed to evaluate the role of novel inflammatory markers in ACS. A secondary goal of this substudy is to determine whether levels of inflammatory markers are reduced by early aggressive simvastatin therapy and whether this anti-inflammatory effect of simvastatin is directly associated with a reduction in cardiovascular events.
Safety
Adverse events are recorded at study visits by the investigator and reviewed by an independent data and safety monitoring committee. During the A phase, platelet counts and bleeding complications are monitored and tirofiban is discontinued if clinically warranted. During the Z phase, the development of hepatic dysfunction or myopathy are grounds for repeat testing and, if persistent, treatment discontinuation.
Statistical analysis
The primary efficacy and safety analyses are based on the intent-to-treat population (unfractionated heparin or LMWH for A phase or to aggressive or accepted care for Z phase). A perprotocol analysis also will be performed that excludes violators of major inclusion/ exclusion criteria and patients nonadherent to the treatment regimen. An interaction term of ST elevation and treatment group is included in the model for the Zphase analysis to test whether the treatment effects are consistent among the STE-ACS and nSTE-ACS groups. All safety analyses exclude data obtained after a patient permanently discontinues use of study medication. Cox regression analyses will be used to compare the incidence of clinical events in the different treatment groups. Subgroup analyses will be performed using covariates for baseline risk defined before initiation of the study.
A-phase sample size
An estimated 5200 patients with nSTE-ACS will be randomized into the A phase. Assuming that the event rate in the unfractionated heparin group is 12.9% (as it was in Platelet Receptor Inhibition for Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms [PRISM-PLUS]) and that the probability of an event with enoxaparin is 10% lower than that with unfractionated heparin, a sample size of 5200 patients (2600 per treatment group) gives approximately 89% power to meet the noninferiority definition. Enoxaparin is considered to have efficacy no worse than (noninferior to) that of unfractionated heparin if the upper 1-sided 95% confidence boundary for the enoxaparin effect relative to unfractionated heparin is below 1.1444. Enoxaparin is considered superior if the 2-sided 95% confidence boundary is below 1.
Z-phase sample size
The power calculation for the A-to-Z Trial is based on the event rate in the PRISM-PLUS trial, which compared tirofiban/unfractionated heparin combined therapy with unfractionated heparin alone in a similar patient population. 2 Following up the trial population until a total of 970 patients have had a primary end point gives the trial 90% power to detect a 20% reduction in hazard rate with a 2-sided P value of less than .05. Similarly, there is 80% power to detect a 17.5% reduction in hazard rate. To complete the trial in a desired time frame, approximately 4500 patients will be randomized into the Z phase. Mechanisms for sample size adjustment are included in the protocol.
Discussion
The A-to-Z trial is a single study designed to address 2 separate but temporally related clinical questions concerning the management of patients with ACS. The primary objective examines whether early aggressive simvastatin therapy is superior to an "accepted care" regimen as a prevention measure for nSTE-ACS or STE-ACS patients. The secondary objective examines whether randomization to either enoxaparin or unfractionated heparin affects the outcome of the acute management in patients with nSTE-ACS who receive aspirin and the GP IIb/IIIa agent tirofiban. Certain key issues regarding the design and implementation of this trial are either unique or potentially controversial.
In the A-to-Z Trial, 2 separate investigations are performed in one patient population, which increases efficiency and decreases cost. Another tangible benefit of this approach is that more questions can be answered in a shorter time period, allowing rapid dissemination of information and translation into clinical practice. This trial design could serve as a model for future studies in patients with non-STE ACS.
The 4-month placebo period at the start of the "accepted care" arm of this trial is controversial. In the American College of Cardiology/AHA Unstable Angina Guidelines initiation of lipid lowering at hospital discharge received a class 1 recommendation for most individuals who have ACS. 15 This recommendation is largely based on preventing the hazard of failing to institute lipid lowering rather than any documented clinical benefit for early treatment. For patients enrolled into a trial, this hazard does not exist.
At the inception of this trial, neither trial data nor community prescribing surveillance data supported early treatment with a statin after myocardial infarction as a standard of care. 16, 17 Surrogate end points from small studies, post hoc analyses of randomized trials not designed to evaluate lipid-lowering therapy, and analyses of registries have emerged during the early enrollment into the A-to-Z Trial that support a benefit for early statin use after ACS. 10, 18, 19 In the Swedish Register of Information on and Knowledge About Swedish Heart Intensive Care Admission (RIKS-HIA) rigorous statistical corrections to eliminate bias found that early statin use was associated with an adjusted 25% relative risk reduction for death. Despite these statistical corrections, the authors noted that their data "cannot replace a randomized controlled trial" and should be confirmed by the ongoing trials. 19 This situation is similar to the case of estrogen in the immediate post-myocardial infarction period. Observational studies suggested a clear benefit of estrogen therapy for reducing cardiac events among women with coronary disease, 20 but the Heart and Estrogen-Progestin Replacement Study (HERS) trial found no overall benefit when estrogen and progesterone were initiated early after myocardial infarction and found an unexpected hazard in the first year of therapy. 21 Currently, the Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) and Cholesterol and Recurrent Events (CARE) trials 7, 8 define the efficacy of secondary prevention with a statin in patients with total cholesterol levels below 250 mg/dL. In LIPID, no patient received active therapy before 4.5 months after the index event because of a 3-month eligibility requirement and a 6-week placebo run-in phase. 22 In CARE, the mean time to enrollment after the index myocardial infarction was 10 months, and only 208 patients received therapy within the first 4 months after the index event. These seminal clinical trials are insufficient for evaluating the effect on clinical outcomes of initiating statin therapy within the first 4 months after an acute coronary event.
One trial, the MIRACL study, has evaluated the efficacy and safety of early aggressive statin use after admission for nSTE-ACS. 12 With the exception of the inclusion of patients with STE-ACS into A-to-Z Trial, the 2 trials appear to be similar in design, but key differences exist.
MIRACL mandated an initial conservative approach for nSTE-ACS management without specifying a uniform optimal medical treatment regimen. The recently reported Treat Angina With Aggrastat and Determine Cost of Therapy With an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction (TACTICS-TIMI 18) trial found that an aggressive early revascularization strategy, performed on a background of tirofiban therapy, significantly reduces the likelihood of death, myocardial infarction, and rehospitalization for ischemia after ACS. 23 A large meta-analysis of medical treatment alone with GP IIb/IIIa agents in ACS found that their early use would result in 20 fewer events for the composite end points of death or nonfatal myocardial infarction at 30 days and 30 fewer deaths, nonfatal myocardial infarctions, or revascularizations at 30 days per 1000 patients treated. 24 Treatment with atrovastatin in the noninvasively managed MIRACL population was associated with a marginally significant (P = .048) reduction in the composite end point of death, recurrent myocardial infarction, resuscitated sudden death, and refractory ischemia. The composite end point was driven almost entirely by reduction in ischemia and not by reduction in the more important components of death and myocardial infarction. Most patients who were enrolled in MIRACL met current AHA and European ACS guideline criteria for initiation of treatment with a GP IIb/IIIa receptor blocker agents (dynamic ST changes or elevated cardiac biomarkers), but only about 1% of the patients received such drugs. Thus it is not clear that early statin use would be beneficial in a patient population managed with a more aggressive pharmacologic or revascularization strategy than was used in MIRACL.
Other key differences between these trials include the different follow-up periods of the trials (16 weeks for MIRACL vs an estimated 24-30 months for the A-to-Z Trial), provisions for early revascularization or conservative treatment in the A-to-Z Trial, and inclusion of STE-ACS patients in the A-to-Z Trial. The wider spectrum of patients with ACS will result in broad applicability of the results.
The secondary question addressed by this trial is the role-additive, neutral, or potentially harmful-of the LMWH enoxaparin in combination with tirofiban and aspirin in patients with nSTE-ACS. Given that the 2 drug classes act on different components of the acute thrombotic process, determining their combination could produce additive or even synergistic effects on adverse clinical events is an important and unanswered question. Two relatively small pilot studies examining the combination of tirofiban with enoxaparin suggest that simultaneous use of the 2 agents is safe and results in a trend toward improved platelet inhibition, 5, 6 but a large prospective trial is needed to define care in this area. The A phase of the A-to-Z Trial has sufficient power to provide initial insight into this important question.
Conclusion
The A-to-Z Trial has 2 distinct aims. The primary aim is to define further the role of statin therapy in the treatment of coronary disease. The secondary aim is to advance acute medical therapy for the stabilization of ACS. The design follows the temporal course of a typical hospital admission for ACS, beginning with initial evaluation and acute therapy, followed by stabilization and secondary evaluation, and concluding with initiation of secondary prevention measures. The results of this study should provide a better understanding of the incremental impact of early statin use on coronary outcomes for patients who have an ACS and who receive contemporary care. The outcome of the A-to-Z Trial could result in the development of a new standard of care if treatment efficacy mirrors or exceeds that found with atorvastatin in MIRACL. Finally, for the subset of patients with ACS who have nSTE-ACS, it will provide the first large-scale evaluation of the safety and efficacy of combined use of LMWH and GP IIb/IIIa agents.
